Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...
Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...
Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...
The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...
SurvivorNet on MSN
Could timing give your cancer treatment a boost? New study on the best time to receive immunotherapy & chemo for non-small cell lung cancer
A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...
Yesterday, the U.S. Food and Drug Administration approved the first blood-based genetic test that can detect gene mutations in non-small cell lung cancer patients. The cobas EGFR Mutation Test v2 is a ...
A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from ...
What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.
Low-dose CT scan helps detect lung cancer early, improving survival. Learn who needs LDCT screening, its benefits, risks and how it saves lives.
Though smoking is the most prevalent risk factor, it does not imply that non-smokers are at zero risk. of lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results